Bexxar is another monoclonal antibody that is being tested but is not yet approved for Non-Hodgkin lymphoma. It has a radioactive iodine molecule attached to, and also binds to the surface of B-cells. Side effects are similar to those caused by Rituxan, but the patient is advised to take an oral iodine supplement in order to protect its thyroid from any damage caused by radioactive iodine. Bexxar has been tested on low-grade NHL and one third of the patients had a complete remission, and 70% responded well to the treatment.
It is possible for the patient to develop an immune response against the antibody because this is a foreign substance too, but such cases are rare and appear mostly in the patients that did not have chemotherapy and have a less affected immune system.
Oncolym is another monoclonal antibody that is being tested. Results recommend it for a more aggressive form of NHL.
Before replacing the standard treatment, monoclonal antibodies have to be tested more and secure doses must be established for preventing other damages to install in the human body. total2page:
Pre [1] 2 Next